Do Kim
Stock Analyst at Piper Sandler
(1.86)
# 2,132
Out of 4,479 analysts
84
Total ratings
42.62%
Success rate
-1.69%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $45.14 | +39.57% | 13 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $8.09 | +468.60% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $473.78 | -37.52% | 11 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $68.40 | +63.74% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $20.33 | +327.94% | 4 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.89 | +695.85% | 2 | Jan 19, 2023 | |
| AFMD Affimed | Maintains: Overweight | $70 → $60 | $5.16 | +1,063.92% | 6 | Dec 12, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $1 → $2 | $8.42 | -76.25% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $8.37 | +413.74% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $22.15 | +44.47% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $2.77 | +694.22% | 4 | Jul 26, 2022 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $19 | $7.63 | +149.02% | 3 | Jun 23, 2022 | |
| MORF Morphic Holding | Maintains: Outperform | n/a | $31.28 | - | 1 | May 3, 2021 | |
| NUVB Nuvation Bio | Initiates: Outperform | n/a | $2.98 | - | 1 | Mar 8, 2021 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Market Perform | n/a | $247.61 | - | 10 | Jan 25, 2021 | |
| XCUR Exicure | Initiates: Outperform | n/a | $0.31 | - | 1 | Dec 18, 2020 | |
| HALO Halozyme Therapeutics | Upgrades: Outperform | n/a | $51.30 | - | 6 | Jan 9, 2020 | |
| VBIV VBI Vaccines | Maintains: Outperform | n/a | $0.71 | - | 2 | Jul 27, 2018 | |
| FATE Fate Therapeutics | Maintains: Outperform | n/a | $3.22 | - | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $45.14
Upside: +39.57%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $8.09
Upside: +468.60%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $473.78
Upside: -37.52%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $68.40
Upside: +63.74%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $20.33
Upside: +327.94%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.89
Upside: +695.85%
Affimed
Dec 12, 2022
Maintains: Overweight
Price Target: $70 → $60
Current: $5.16
Upside: +1,063.92%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $1 → $2
Current: $8.42
Upside: -76.25%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $8.37
Upside: +413.74%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $22.15
Upside: +44.47%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $2.77
Upside: +694.22%
Scholar Rock Holding
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $7.63
Upside: +149.02%
Morphic Holding
May 3, 2021
Maintains: Outperform
Price Target: n/a
Current: $31.28
Upside: -
Nuvation Bio
Mar 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.98
Upside: -
Alnylam Pharmaceuticals
Jan 25, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $247.61
Upside: -
Exicure
Dec 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.31
Upside: -
Halozyme Therapeutics
Jan 9, 2020
Upgrades: Outperform
Price Target: n/a
Current: $51.30
Upside: -
VBI Vaccines
Jul 27, 2018
Maintains: Outperform
Price Target: n/a
Current: $0.71
Upside: -
Fate Therapeutics
Mar 6, 2018
Maintains: Outperform
Price Target: n/a
Current: $3.22
Upside: -